| Report Code: 40246 | Report Type: Indication Pipeline Reports | Pages: 300+ | Available format: |
| Therapeutic Area(s): | Oncology |
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Drugs by Phase
1.3.2 Pipeline Drugs by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By geography
2.2.1.3 By designation
2.2.2 Key Opinion Leaders (KOLs) Validation
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Disease Overview
4.2 Causes and Risk Factors
4.3 Prognosis
4.4 Sign and Symptoms
4.5 Pathophysiology
4.6 Diagnosis
4.7 Treatment
4.8 Treatment Algorithm for Pancreatic Cancer
4.9 Key Drivers
4.9.1 Rising Incidence of Pancreatic Cancer
4.9.2 Increasing Awareness
4.9.3 Rising R&D Investments
4.9.4 Rising Number of Product Launches
4.10 Key Barriers
4.10.1 Late Observation of Signs and Symptoms at its Early Stage
4.10.2 Patent Expiry of Blockbuster Drugs
4.10.3 High Treatment Cost of Current Treatment
4.11 Opportunities
4.11.1 Aftermath of Current Treatments
4.12 Technology Overview
4.13 Drug Designations
4.14 Unmet Medical Needs
4.14.1 Improvement in Drug Efficacy
4.14.2 Early Diagnosis
4.14.3 Increasing Usage of Available Approved Therapy
4.14.4 Need of Defined Treatment Algorithm
4.14.5 Improvement Required in 3rd Line Settings
Chapter 5. Pipeline Drugs Outlook
5.1 Pancreatic Cancer Pipeline Drugs Snapshot
5.1.1 Pipeline Drugs Snapshot by Phase
5.1.2 Pipeline Drugs Snapshot by Route of Administration
5.1.3 Pipeline Drugs Snapshot by Molecule Type
5.1.4 Pipeline Drugs Snapshot by Company
Chapter 6. Pancreatic Cancer Pipeline Drugs Analysis
6.1 Phase III
6.1.1 Masitinib
6.1.1.1 Pre-clinical results
6.1.1.2 Clinical trials
6.1.1.3 Clinical trial results
6.1.1.4 Designations
6.1.1.5 Patents
6.1.2 XXXX
6.1.2.1 Pre-clinical results
6.1.2.2 Clinical trials
6.1.2.3 Clinical trial results
6.1.2.4 Designations
6.1.3 XXXX
6.1.3.1 Clinical trials
6.1.3.2 Clinical trial results
6.1.4 XXXX
6.1.4.1 Pre-clinical trials
6.1.4.2 Clinical trials
6.1.4.3 Clinical trial results
6.1.4.4 Strategic developments
6.1.4.5 Designations
6.1.4.6 Financing
6.1.4.7 Patents
6.1.5 XXXX
6.1.5.1 Clinical trials
6.1.5.2 Clinical trial results
6.1.5.3 Designations
6.1.6 XXXX
6.1.6.1 Pre-clinical results
6.1.6.2 Clinical trials
6.1.6.3 Clinical trial results
6.1.6.4 Strategic developments
6.1.6.5 Designations
6.1.7 XXXX
6.1.7.1 Clinical trials
6.1.7.2 Clinical trial results
6.1.7.3 Strategic developments
6.1.7.4 Designations
6.2 Phase II
6.2.1 Pamrevlumab
6.2.1.1 Clinical trials
6.2.1.2 Clinical trial results
6.2.1.3 Designations
6.2.2 XXXX
6.2.2.1 Pre-clinical results
6.2.2.2 Clinical trials
6.2.2.3 Clinical trial results
6.2.2.4 Designations
6.2.3 XXXX
6.2.3.1 Pre-clinical studies
6.2.3.2 Clinical trials
6.2.3.3 Clinical trial results
6.2.3.4 Strategic developments
6.2.4 XXXX
6.2.4.1 Pre-clinical studies
6.2.4.2 Clinical trials
6.2.4.3 Clinical trial results
6.2.4.4 Strategic developments
6.2.4.5 Designations
6.2.5 XXXX
6.2.5.1 Pre-clinical studies
6.2.5.2 Clinical trials
6.2.5.3 Clinical trial results
6.2.5.4 Designations
6.2.6 XXXX
6.2.6.1 Pre-clinical results
6.2.6.2 Clinical trials
6.2.6.3 Clinical trial results
6.2.6.4 Technology
6.2.6.5 Designations
6.2.6.6 Patents
6.2.7 XXXX
6.2.7.1 Clinical trials
6.2.7.2 Clinical trial results
6.2.8 XXXX
6.2.8.1 Clinical trials
6.2.8.2 Clinical trial results
6.2.8.3 Designations
6.2.8.4 Strategic developments
6.2.8.5 Patents
6.2.9 XXXX
6.2.9.1 Pre-clinical studies
6.2.9.2 Clinical trials
6.2.9.3 Clinical trial results
6.2.9.4 Strategic developments
6.2.10 XXXX
6.2.10.1 Clinical trials
6.2.10.2 Clinical trial results
6.2.10.3 Designations
6.2.10.4 Technology
6.2.11 XXXX
6.2.11.1 Clinical trials
6.2.12 XXXX
6.2.12.1 Clinical trials
6.2.12.2 Clinical trial results
6.2.12.3 Strategic developments
6.2.13 XXXX
6.2.13.1 Pre-clinical studies
6.2.13.2 Clinical trials
6.2.14 XXXX
6.2.14.1 Clinical trials
6.2.14.2 Strategic developments
6.2.14.3 Technology
6.2.15 XXXX
6.2.15.1 Clinical trials
6.2.15.2 Designations
6.2.15.3 Patents
6.2.16 XXXX
6.2.16.1 Clinical trials
6.2.16.2 Clinical trial results
6.2.16.3 Technology
6.2.17 XXXX
6.2.17.1 Clinical trials
6.2.17.2 Clinical trial results
6.2.18 XXXX
6.2.18.1 Pre-clinical studies
6.2.18.2 Clinical trials
6.2.18.3 Clinical trial results
6.2.19 XXXX
6.2.19.1 Pre-clinical studies
6.2.19.2 Clinical trials
6.2.19.3 Clinical trial results
6.2.19.4 Strategic developments
6.2.19.5 Designations
6.2.20 XXXX
6.2.20.1 Clinical trials
6.2.20.2 Strategic developments
6.2.20.3 Financing
6.2.21 XXXX
6.2.21.1 Clinical trials
6.2.21.2 Strategic developments
6.2.21.3 List of other Phase II drugs
6.3 Phase I
6.3.1 Resminostat
6.3.1.1 Pre-clinical results
6.3.1.2 Clinical trials
6.3.1.3 Clinical trial results
6.3.1.4 Strategic developments
6.3.2 XXXX
6.3.2.1 Clinical trials
6.3.2.2 Clinical trial results
6.3.2.3 Strategic developments
6.3.2.4 Patents
6.3.3 XXXX
6.3.3.1 Clinical trials
6.3.3.2 Clinical trial results
6.3.3.3 Patents
6.3.4 XXXX
6.3.4.1 Pre-clinical studies
6.3.4.2 Clinical trials
6.3.4.3 Clinical trial results
6.3.4.4 Strategic developments
6.3.4.5 Designations
6.3.4.6 Patents
6.3.5 XXXX
6.3.5.1 Pre-clinical studies
6.3.5.2 Clinical trials
6.3.5.3 Clinical trial results
6.3.5.4 Patents
6.3.6 XXXX
6.3.6.1 Pre-clinical results
6.3.6.2 Clinical trials
6.3.6.3 Patent
6.3.7 XXXX
6.3.7.1 Pre-clinical results
6.3.7.2 Clinical trials
6.3.7.3 Patent
6.3.8 XXXX
6.3.8.1 Pre-clinical results
6.3.8.2 Clinical trials
6.3.8.3 Clinical trial results
6.3.8.4 Designations
6.3.8.5 Technology
6.3.9 XXXX
6.3.9.1 Pre-clinical results
6.3.9.2 Clinical trials
6.3.9.3 Clinical trial results
6.3.9.4 Strategic developments
6.3.9.5 Patent
6.3.10 XXXX
6.3.10.1 Clinical trials
6.3.10.2 Clinical trial results
6.3.10.3 Financing
6.3.10.4 Patent
6.3.11 XXXX
6.3.11.1 Pre-clinical studies
6.3.11.2 Clinical trials
6.3.11.3 Clinical trial results
6.3.11.4 Strategic developments
6.3.11.5 Grants
6.3.12 XXXX
6.3.12.1 Clinical trials
6.3.12.2 Strategic developments
6.3.12.3 Patents
6.3.13 XXXX
6.3.13.1 Pre-clinical studies
6.3.13.2 Clinical trials
6.3.13.3 Strategic developments
6.3.13.4 Designations
6.3.13.5 Patents
6.3.14 XXXX
6.3.14.1 Clinical trials
6.3.15 XXXX
6.3.15.1 Pre-clinical studies
6.3.15.2 Clinical trials
6.3.15.3 Clinical trial results
6.3.15.4 Strategic developments
6.3.15.5 Patents
6.3.15.6 List of other Phase I drugs
6.4 Pre-Clinical
6.4.1 OMTX705
6.4.1.1 Pre-clinical studies
6.4.2 XXXX
6.4.2.1 Pre-clinical studies
6.4.2.2 Strategic developments
6.4.2.3 Technology
6.4.3 XXXX
6.4.3.1 Pre-clinical studies
6.4.3.2 Strategic developments
6.4.3.3 Technology
6.4.4 XXXX
6.4.4.1 Pre-clinical studies and results
6.4.5 XXXX
6.4.6 XXXX
6.4.6.1 Pre-clinical studies
6.4.6.2 Technology
6.4.6.3 Strategic developments
6.4.7 XXXX
6.4.7.1 Technology
6.4.8 XXXX
6.4.8.1 Technology
6.4.8.2 Patents
6.4.9 XXXX
6.4.9.1 Pre-clinical studies
6.4.10 XXXX
6.4.10.1 Technology
6.4.11 XXXX
6.4.11.1 Designations
6.4.12 XXXX
6.4.12.1 Pre-clinical studies
6.4.12.2 Strategic developments
6.4.13 XXXX
6.4.13.1 Pre-clinical studies
6.4.13.2 Technology
6.4.13.3 Strategic developments
6.4.14 XXXX
6.4.14.1 Pre-clinical studies
6.4.14.2 Technology
6.4.14.3 Designations
6.4.15 XXXX
6.4.16 List of Other Pre-Clinical Drugs
6.5 Discovery
6.5.1 NBE-003
6.5.1.1 Strategic developments
6.5.1.2 Technology
6.5.2 XXXX
6.5.3 XXXX
6.5.4 XXXX
6.5.5 XXXX
6.5.5.1 Technology
Chapter 7. Clinical Trials Review
7.1 Clinical Trials by Geography
7.2 Clinical Trials by Trial Status
Chapter 8. Regulatory Framework for Drug Approval
8.1 U.S.
8.2 Europe
8.2.1 Centralized Procedure
8.2.2 Mutual Recognition Procedure
8.2.3 Decentralized Procedure
8.2.4 Nationalized Procedures
8.3 Japan
Chapter 9. Competitive Landscape
9.1 Summary of Strategic Development Activities
9.2 Comparative Analysis
9.3 Attribute Analysis
9.3.1 Safety
9.3.2 Efficacy
9.3.3 USP
9.4 Expected Launch Time of Phase III Clinical Stage Products
9.5 Key Winning Strategies
9.5.1 Technological Advancements
9.5.2 Collaborations
9.5.3 Development through Subsidiaries
9.5.4 Acquisition of Additional Pipeline Products
9.6 Pharma Proff’s View
Chapter 10. Company Profiles
10.1 AB Science S.A.
10.1.1 Business Overview
10.1.2 Product and Service Offerings
10.2 XXXX.
10.2.1 Business Overview
10.2.2 Product and Service Offerings
10.2.2.1 Marketed products
10.2.2.2 Pipeline products
10.3 XXXX
10.3.1 Business Overview
10.3.2 Product and Service Offerings
10.4 XXXX
10.4.1 Business Overview
10.4.2 Product and Service Offerings
10.4.2.1 Marketed products
10.4.2.2 Pipeline products
10.5 XXXX.
10.5.1 Business Overview
10.5.2 Product and Service Offerings
10.5.2.1 Marketed products
10.5.2.2 Pipeline products
10.6 XXXX.
10.6.1 Business Overview
10.6.2 Product and Service Offerings
10.6.2.1 Marketed products
10.6.2.2 Pipeline products
10.7 XXXX
10.7.1 Business Overview
10.7.2 Product and Service Offerings
10.8 XXXX.
10.8.1 Business Overview
10.8.2 Product and Service Offerings
10.9 XXXX
10.9.1 Business Overview
10.9.2 Product and Service Offerings
10.10 XXXX
10.10.1 Business Overview
10.10.2 Product and Service Offerings
10.10.2.1 Marketed products
10.10.2.2 Pipeline products
10.11 XXXX.
10.11.1 Business Overview
10.11.2 Product and Service Offerings
10.12 XXXX
10.12.1 Business Overview
10.12.2 Product and Service Offerings
10.12.2.1 Marketed products
10.12.2.2 Pipeline products
10.13 XXXX
10.13.1 Business Overview
10.13.2 Product and Service Offerings
10.13.2.1 Marketed products
10.13.2.2 Pipeline products
10.14 XXXX
10.14.1 Business Overview
10.14.2 Product and Service Offerings
10.14.2.1 Marketed products
10.14.2.2 Pipeline products
10.15 XXXX
10.15.1 Business Overview
10.15.2 Product and Service Offerings
10.16 XXXX.
10.16.1 Business Overview
10.16.2 Product and Service Offerings
10.16.2.1 Marketed products
10.16.2.2 Pipeline products
10.17 XXXX.
10.17.1 Business Overview
10.17.2 Product and Service Offerings
10.18 XXXX
10.18.1 Business Overview
10.18.2 Product and Service Offerings
10.18.2.1 Marketed products
10.18.2.2 Pipeline products
10.19 XXXX.
10.19.1 Business Overview
10.19.2 Product and Service Offerings
10.20 XXXX.
10.20.1 Business Overview
10.20.2 Product and Service Offerings
Chapter 11. Appendix
11.1 Recently Organized/Held Seminars and Conferences
11.2 Upcoming Conferences
11.3 Sources & References
11.4 Abbreviations
11.5 Related Reports
LIST OF TABLES
TABLE 1 PANCREATIC CANCER EPIDEMIOLOGY FOR 7MM (2016-2021)
TABLE 2 PANCREATIC CANCER EPIDEMIOLOGY FOR 7MM (2022-2028)
TABLE 3 DESIGNATIONS FOR SOME PANCREATIC CANCER DRUGS
TABLE 4 DESCRIPTION OF MASITINIB
TABLE 5 CLINICAL TRIALS OF MASITINIB
TABLE 6 DESCRIPTION OF XXXX
TABLE 7 CLINICAL TRIALS OF XXXX
TABLE 8 DESCRIPTION OF XXXX
TABLE 9 CLINICAL TRIALS OF XXXX
TABLE 10 DESCRIPTION OF XXXX
TABLE 11 CLINICAL TRIALS OF XXXX
TABLE 12 DESCRIPTION OF XXXX
TABLE 13 CLINICAL TRIALS OF XXXX
TABLE 14 DESCRIPTION OF XXXX
TABLE 15 CLINICAL TRIALS OF XXXX
TABLE 16 DESCRIPTION OF XXXX
TABLE 17 CLINICAL TRIALS OF XXXX
TABLE 18 DESCRIPTION OF PAMREVLUMAB
TABLE 19 CLINICAL TRIALS OF PAMREVLUMAB
TABLE 20 DESCRIPTION OF XXXX
TABLE 21 CLINICAL TRIALS OF XXXX
TABLE 22 DESCRIPTION OF XXXX
TABLE 23 CLINICAL TRIALS OF XXXX
TABLE 24 DESCRIPTION OF XXXX
TABLE 25 CLINICAL TRIALS OF XXXX
TABLE 26 DESCRIPTION OF XXXX
TABLE 27 CLINICAL TRIALS OF XXXX
TABLE 28 DESCRIPTION OF XXXX
TABLE 29 CLINICAL TRIALS OF XXXX
TABLE 30 PATENTS OF XXXX
TABLE 31 DESCRIPTION OF XXXX
TABLE 32 CLINICAL TRIALS OF XXXX
TABLE 33 DESCRIPTION OF XXXX
TABLE 34 CLINICAL TRIALS OF XXXX
TABLE 35 PATENTS OF XXXX
TABLE 36 DESCRIPTION OF XXXX
TABLE 37 CLINICAL TRIALS OF XXXX
TABLE 38 DESCRIPTION OF XXXX
TABLE 39 CLINICAL TRIALS OF XXXX
TABLE 40 DESCRIPTION OF XXXX
TABLE 41 CLINICAL TRIALS OF XXXX
TABLE 42 DESCRIPTION OF XXXX
TABLE 43 CLINICAL TRIALS OF XXXX
TABLE 44 DESCRIPTION OF XXXX
TABLE 45 CLINICAL TRIALS OF XXXX
TABLE 46 DESCRIPTION OF XXXX
TABLE 47 CLINICAL TRIALS OF XXXX
TABLE 48 DESCRIPTION OF XXXX
TABLE 49 CLINICAL TRIALS OF XXXX
TABLE 50 PATENTS OF XXXX
TABLE 51 DESCRIPTION OF XXXX
TABLE 52 CLINICAL TRIALS OF XXXX
TABLE 53 DESCRIPTION OF XXXX
TABLE 54 CLINICAL TRIALS OF XXXX
TABLE 55 DESCRIPTION OF XXXX
TABLE 56 CLINICAL TRIALS OF XXXX
TABLE 57 DESCRIPTION OF XXXX
TABLE 58 CLINICAL TRIALS OF XXXX
TABLE 59 DESCRIPTION OF XXXX
TABLE 60 CLINICAL TRIALS OF XXXX
TABLE 61 DESCRIPTION OF XXXX
TABLE 62 CLINICAL TRIALS OF XXXX
TABLE 63 OTHER PHASE II DRUGS
TABLE 64 DESCRIPTION OF RESMINOSTAT
TABLE 65 CLINICAL TRIALS OF RESMINOSTAT
TABLE 66 DESCRIPTION OF XXXX
TABLE 67 CLINICAL TRIALS OF XXXX
TABLE 68 PATENTS OF GALUNISERTIB
TABLE 69 DESCRIPTION OF XXXX
TABLE 70 CLINICAL TRIALS OF XXXX
TABLE 71 PATENTS OF XXXX
TABLE 72 DESCRIPTION OF XXXX
TABLE 73 CLINICAL TRIALS OF XXXX
TABLE 74 DESCRIPTION OF XXXX
TABLE 75 CLINICAL TRIALS OF XXXX
TABLE 76 PATENTS OF XXXX
TABLE 77 DESCRIPTION OF XXXX
TABLE 78 CLINICAL TRIALS OF XXXX
TABLE 79 PATENTS OF XXXX
TABLE 80 DESCRIPTION OF XXXX
TABLE 81 CLINICAL TRIALS OF XXXX
TABLE 82 PATENTS OF XXXX
TABLE 83 DESCRIPTION OF XXXX
TABLE 84 CLINICAL TRIALS OF XXXX
TABLE 85 DESCRIPTION OF XXXX
TABLE 86 CLINICAL TRIALS OF XXXX
TABLE 87 PATENTS OF XXXX
TABLE 88 DESCRIPTION OF XXXX
TABLE 89 CLINICAL TRIALS OF XXXX
TABLE 90 PATENTS OF XXXX
TABLE 91 DESCRIPTION OF XXXX
TABLE 92 CLINICAL TRIALS OF XXXX
TABLE 93 DESCRIPTION OF XXXX
TABLE 94 CLINICAL TRIALS OF XXXX
TABLE 95 PATENTS OF XXXX
TABLE 96 DESCRIPTION OF XXXX
TABLE 97 CLINICAL TRIALS OF XXXX
TABLE 98 PATENTS OF XXXX
TABLE 99 DESCRIPTION OF XXXX
TABLE 100 CLINICAL TRIALS OF XXXX
TABLE 101 DESCRIPTION OF XXXX
TABLE 102 CLINICAL TRIALS OF XXXX
TABLE 103 PATENT OF XXXX
TABLE 104 OTHER PHASE I DRUGS
TABLE 105 DESCRIPTION OF OMTX705
TABLE 106 DESCRIPTION OF XXXX
TABLE 107 DESCRIPTION OF XXXX
TABLE 108 DESCRIPTION OF XXXX
TABLE 109 DESCRIPTION OF XXXX
TABLE 110 DESCRIPTION OF XXXX
TABLE 111 DESCRIPTION OF XXXX
TABLE 112 DESCRIPTION OF XXXX
TABLE 113 DESCRIPTION OF XXXX
TABLE 114 DESCRIPTION OF XXXX
TABLE 115 DESCRIPTION OF XXXX
TABLE 116 DESCRIPTION OF XXXX
TABLE 117 DESCRIPTION OF XXXX
TABLE 118 DESCRIPTION OF XXXX
TABLE 119 DESCRIPTION OF XXXX
TABLE 120 OTHER PRE-CLINICAL DRUGS
TABLE 121 DESCRIPTION OF NBE-003
TABLE 122 DESCRIPTION OF XXXX
TABLE 123 DESCRIPTION OF XXXX
TABLE 124 DESCRIPTION OF XXXX
TABLE 125 DESCRIPTION OF MIRNA RESEARCH PROGRAM
TABLE 126 COLLABORATIONS AND LICENSING AGREEMENTS
TABLE 127 MERGERS AND ACQUISITIONS
TABLE 128 OTHER DEVELOPMENTS
TABLE 129 MARKETED DRUGS COMPARISON BASED ON EFFICACY
TABLE 130 COMPARISON OF PHASE III DRUGS
TABLE 131 ATTRIBUTE ANALYSIS
TABLE 132 EXPECTED LAUNCH TIME OF PHASE III CLINICAL STAGE PRODUCTS
TABLE 133 AB SCIENCE S.A. – AT A GLANCE
TABLE 134 PIPELINE PRODUCTS
TABLE 135 XXXX XXXX – AT A GLANCE
TABLE 136 MARKETED PRODUCTS
TABLE 137 PIPELINE PRODUCTS
TABLE 138 XXXX XXXX – AT A GLANCE
TABLE 139 PIPELINE PRODUCTS
TABLE 140 XXXX XXXX – AT A GLANCE
TABLE 141 PIPELINE PRODUCTS
TABLE 142 XXXX XXXX – AT A GLANCE
TABLE 143 PIPELINE PRODUCTS
TABLE 144 XXXX XXXX – AT A GLANCE
TABLE 145 PIPELINE PRODUCTS
TABLE 146 XXXX XXXX – AT A GLANCE
TABLE 147 PIPELINE PRODUCTS
TABLE 148 XXXX XXXX – AT A GLANCE
TABLE 149 PIPELINE PRODUCTS
TABLE 150 XXXX XXXX – AT A GLANCE
TABLE 151 PIPELINE PRODUCTS
TABLE 152 XXXX XXXX – AT A GLANCE
TABLE 153 PIPELINE PRODUCTS
TABLE 154 XXXX XXXX – AT A GLANCE
TABLE 155 XXXX XXXX – AT A GLANCE
TABLE 156 MARKETED PRODUCTS
TABLE 157 XXXX XXXX – AT A GLANCE
TABLE 158 MARKETED PRODUCTS
TABLE 159 PIPELINE PRODUCTS
TABLE 160 XXXX XXXX – AT A GLANCE
TABLE 161 MARKETED PRODUCTS
TABLE 162 PIPELINE PRODUCTS
TABLE 163 XXXX XXXX – AT A GLANCE
TABLE 164 PIPELINE PRODUCTS
TABLE 165 XXXX XXXX – AT A GLANCE
TABLE 166 PIPELINE PRODUCTS
TABLE 167 XXXX XXXX – AT A GLANCE
TABLE 168 PIPELINE PRODUCTS
TABLE 169 XXXX XXXX – AT A GLANCE
TABLE 170 MARKETED PRODUCT
TABLE 171 PIPELINE PRODUCTS
TABLE 172 XXXX XXXX – AT A GLANCE
TABLE 173 PIPELINE PRODUCTS
TABLE 174 SUN BIOPHARMA INC. – AT A GLANCE
TABLE 175 RECENTLY ORGANIZED SEMINARS AND CONFERENCES
TABLE 176 UPCOMING SEMINARS AND CONFERENCES
TABLE 177 SOURCES & REFERENCES
TABLE 178 ABBREVIATIONS
LIST OF FIGURES
FIG 1 RESEARCH METHODOLOGY
FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY GEOGRAPHY
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 5 PATHWAYS AND CELL FUNCTIONS AFFECTED IN EVERY SINGLE PANCREATIC ADENOCARCINOMA
FIG 6 DIAGNOSTIC ALGORITHM FOR SUSPECTED PANCREATIC CANCER
FIG 7 TREATMENT ALGORITHM FOR PANCREATIC CANCER
FIG 8 PANCREATIC CANCER INCIDENT CASES, BY STAGE FOR 7MM (2016-2028)
FIG 9 UNMET NEEDS – PANCREATIC CANCER
FIG 10 PANCREATIC CANCER PIPELINE DRUGS SNAPSHOT, BY PHASE (2019)
FIG 11 PANCREATIC CANCER PIPELINE DRUGS SNAPSHOT, BY ROUTE OF ADMINISTRATION (2019)
FIG 12 PANCREATIC CANCER PIPELINE DRUGS SNAPSHOT, BY MOLECULE TYPE (2019)
FIG 13 COMPANY BENCHMARKING BASED ON DRUG CANDIDATES
FIG 14 BREAKDOWN OF CLINICAL TRIALS, BY GEOGRAPHY
FIG 15 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 16 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)
FIG 17 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)
FIG 18 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU
FIG 19 MARKETING AUTHORIZATION PROCEDURES IN EU
FIG 20 CENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 21 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL
FIG 22 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL
FIG 23 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN
FIG 24 MARKET SHARE OF PANCREATIC CANCER MARKETED DRUGS (2018)
FIG 25 EXPECTED LAUNCH TIME